Beta-glucan and CD40 agonist combination immunotherapy for the treatment of pancreatic cancer
Patent Information
- Application Number
- DE602019084231
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-03-13
- Filing Date
- 2019-03-13
- Publication Date
- 2026-04-29
- Estimated Expiration
- 2039-03-13
AI Technical Summary
Existing immunotherapies for cancer, such as those targeting CD40 agonists and β-glucans, often show limited efficacy due to immune suppressive tumor microenvironments and lack of T cell-dependent antitumor activity, especially in poorly immunogenic tumors like pancreatic cancer.
Combining soluble β(1,6)-[poly-(1,3)-D-glucopyranosyl]-poly-β(1,3)-D-glucopyranose β-glucan with a CD40 agonist, such as an agonistic CD40 antibody, to re-polarize myeloid cells and activate antigen-presenting cells, enhancing T cell-dependent antitumor immunity.
The combination therapy achieves significant tumor regression and improved overall survival in murine models of pancreatic cancer by inducing potent T cell-dependent antitumor activity, even in the absence of chemotherapy, with synergistic effects dependent on CD4 and CD8 T cells.